Compounds > olmesartan
Page last updated: 2024-09-04

olmesartan and warfarin

olmesartan has been researched along with warfarin in 5 studies

Compound Research Comparison

Studies
(olmesartan)		Trials
(olmesartan)		Recent Studies (post-2010)
(olmesartan)		Studies
(warfarin)		Trials
(warfarin)		Recent Studies (post-2010) (warfarin)
84118555436,5732,14314,728

Protein Interaction Comparison

ProteinTaxonomyolmesartan (IC50)warfarin (IC50)
Vitamin K epoxide reductase complex subunit 1 Homo sapiens (human)0.0088

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ekins, S; Williams, AJ; Xu, JJ1
Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Kirch, W; Laeis, P; Püchler, K1
Ikeda, T; Kamiyama, E; Kasuya, A; Kurihara, A; Takei, M; Yoshigae, Y1

Other Studies

5 other study(ies) available for olmesartan and warfarin

ArticleYear
A predictive ligand-based Bayesian model for human drug-induced liver injury.
    Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12

    Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands

2010
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:7

    Topics: Glutathione; Pharmacology; Sulfur Radioisotopes

2011
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction.
    Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 2001, Volume: 19, Issue:1

    Topics: Administration, Oral; Adult; Aluminum Hydroxide; Biological Availability; Blood; Digoxin; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Humans; Hydrolysis; Imidazoles; Injections, Intravenous; Magnesium Hydroxide; Male; Olmesartan Medoxomil; Tetrazoles; Warfarin

2001
Inhibitory effects of angiotensin receptor blockers on CYP2C9 activity in human liver microsomes.
    Drug metabolism and pharmacokinetics, 2007, Volume: 22, Issue:4

    Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Aryl Hydrocarbon Hydroxylases; Chemical Phenomena; Chemistry, Physical; Cytochrome P-450 CYP2C9; Humans; Hydrogen-Ion Concentration; Hydroxylation; Imidazoles; Microsomes, Liver; Models, Biological; Protein Binding; Structure-Activity Relationship; Tetrazoles; Valine; Valsartan; Warfarin

2007